ReviewJournal of nuclear medicine : official publication, Society of Nuclear Medicine2023
Marshalling the Potential of Auger Electron Radiopharmaceutical Therapy.
Review in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 57 citations in OpenAlex.
- Current status of radionuclide therapy targeting PARP in cancer: challenges and prospects.European journal of nuclear medicine and molecular imaging · 2026Review
- Auger Electron Therapy Enhanced by Heat-Triggered Release of I-125-Labeled DNA-Targeted Compounds within the Tumor Microenvironment.Molecular pharmaceutics · 2026Article
- Glycoprotein Mucin 13 Expression as a Theranostic Target in Colorectal Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- High-yield reactor production of terbium-161 using thin-layer gadolinium-160 targets, simplified chloride based separation and radiolabeling of DOTA based ligands.EJNMMI radiopharmacy and chemistry · 2026Article
- Fully GMP-complient radiosynthesis of [EJNMMI radiopharmacy and chemistry · 2026Article
- GATE Monte Carlo evaluation of cellular dosimetry forEJNMMI physics · 2026Article
- Radionuclide‑drug conjugates in lung cancer: advances in precision therapy and clinical translation.Molecular cancer · 2026Review
- Scaling the production of bromine-76 and bromine-77 labeled poly-ADP-ribose-polymerase-targeted theranostics for preclinical use.EJNMMI radiopharmacy and chemistry · 2026Article
- Precision theranostics in oncology: integrating antibody-drug conjugates, radioimmunotherapy, and immuno‑PET for adaptive cancer care.Discover oncology · 2026Review
- Ion Beam Imaging Shows Selective Thallium-201 Uptake in Cell Nuclei: Impact on Cellular Dosimetry and Radiotoxicity of Auger Electron Emitters.Chemical & biomedical imaging · 2026Article
- Radiation Biology of Radiopharmaceuticals: Beyond External Beam Radiation Therapy.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Revisiting the F3 Peptide: In Vitro Investigations of C- and N-Terminally Modified Peptide Conjugates for Radiotracer Development.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Contemporary opportunities and potential of Auger electron-emitting theranostics.Theranostics · 2026Review
- Monte Carlo-based subcellular comparison of electron energy deposition byEJNMMI physics · 2025Article
- Advances in radiopharmaceuticals for cancer radiotheranostics: CCK2R targeting as a paradigm for translational innovation.Cancer communications (London, England) · 2025Review
- Coordination Chemistry of Emerging Meitner-Auger Electron-Emitting Radiometals for Targeted Radionuclide Therapy.Coordination chemistry reviews · 2025Article
- The radioactiveRSC advances · 2025Article
- Mitochondria-tropic radioconjugates to enhance the therapeutic potential of terbium-161.EJNMMI radiopharmacy and chemistry · 2025Article
- Cytotoxicity Comparison ofMolecules (Basel, Switzerland) · 2025Article
- Theranostics for Neuroblastoma: Making Molecular Radiotherapy Work Better.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
Corrections and comments
- Erratum issuedErratum.2026
Authors and funding
9 authors at 9 institutions in 8 countries.
Funding
Abstract
Auger electron (AE) radiopharmaceutical therapy (RPT) may have the same therapeutic efficacy as α-particles for oncologic small disease, with lower risks of normal-tissue toxicity. The seeds of using AE emitters for RPT were planted several decades ago. Much knowledge has been gathered about the potency of the biologic effects caused by the intense shower of these low-energy AEs. Given their short range, AEs deposit much of their energy in the immediate vicinity of their site of decay. However, the promise of AE RPT has not yet been realized, with few agents evaluated in clinical trials and none becoming part of routine treatment so far. Instigated by the 2022 "Technical Meeting on Auger Electron Emitters for Radiopharmaceutical Developments" at the International Atomic Energy Agency, this review presents the current status of AE RPT based on the discussions by experts in the field. A scoring system was applied to illustrate hurdles in the development of AE RPT, and we present a selected list of well-studied and emerging AE-emitting radionuclides. Based on the number of AEs and other emissions, physical half-life, radionuclide production, radiochemical approaches, dosimetry, and vector availability, recommendations are put forward to enhance and impact future efforts in AE RPT research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.